A personalized approach to acute myeloid leukemia therapy: current options

References

• Assi SA, Imperato MR, Coleman DJL, et al. Subtype-specific regulatory network rewiring in acute myeloid leukemia. Nat Genet. 2019;51(1):151–162. doi:10.1038/s41588-018-0270-130420649
   PubMed Web of Science ®Google Scholar
• Ley TJ, Miller C, Ding L, et al. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med. 2013;368(22):2059–2074. doi:10.1056/NEJMoa1301689.23634996
   PubMed Web of Science ®Google Scholar
• Papaemmanuil E, Gerstung M, Bullinger L, et al. Genomic classification and prognosis in acute myeloid leukemia. N Engl J Med. 2016;374(23):2209–2221. doi:10.1056/NEJMoa151619227276561
   PubMed Web of Science ®Google Scholar
• Brinda B, Khan I, Parkin B, Konig H. The rocky road to personalized medicine in acute myeloid leukaemia. J Cell Mol Med. 2018;22(3):1411–1427. doi:10.1111/jcmm.1347829327808
   PubMed Web of Science ®Google Scholar
• De Kouchkovsky I, Abdul-Hay M. Acute myeloid leukemia: a comprehensive review and 2016 update. Blood Cancer J. 2016;6(7):e441. doi:10.1038/bcj.2016.5027367478
   PubMed Web of Science ®Google Scholar
• Rubnitz JE. Current management of childhood acute myeloid leukemia. Paediatr Drugs. 2017;19(1):1–10. doi:10.1007/s40272-016-0200-627785777
   PubMed Web of Science ®Google Scholar
• Friedman AA, Letai A, Fisher DE, Flaherty KT. Precision medicine for cancer with next-generation functional diagnostics. Nat Rev Cancer. 2015;15(12):747–756. doi:10.1038/nrc401526536825
   PubMed Web of Science ®Google Scholar
• Abraham A, Varatharajan S, Karathedath S, et al. RNA expression of genes involved in cytarabine metabolism and transport predicts cytarabine response in acute myeloid leukemia. Pharmacogenomics. 2015;16(8):877–890. doi:10.2217/pgs.15.4426083014
   PubMed Web of Science ®Google Scholar
• Abraham A, Devasia AJ, Varatharajan S, Karathedath S, Balasubramanian P, Mathews V. Effect of cytosine arabinoside metabolizing enzyme expression on drug toxicity in acute myeloid leukemia. Ann Hematol. 2015;94(5):883–885. doi:10.1007/s00277-014-2254-225391240
   PubMed Web of Science ®Google Scholar
• Varatharajan S, Panetta JC, Abraham A, et al. Population pharmacokinetics of Daunorubicin in adult patients with acute myeloid leukemia. Cancer Chemother Pharmacol. 2016;78(5):1051–1058. doi:10.1007/s00280-016-3166-827738808
   PubMed Web of Science ®Google Scholar
• Varatharajan S, Abraham A, Zhang W, et al. Carbonyl reductase 1 expression influences daunorubicin metabolism in acute myeloid leukemia. Eur J Clin Pharmacol. 2012;68(12):1577–1586. doi:10.1007/s00228-012-1291-922562609
   PubMed Web of Science ®Google Scholar
• Elsayed AH, Cao X, Crews KR, et al. Comprehensive Ara-C SNP score predicts leukemic cell intracellular ara-CTP levels in pediatric acute myeloid leukemia patients. Pharmacogenomics. 2018;19(14):1101–1110. doi:10.2217/pgs-2018-008630088438
   PubMed Web of Science ®Google Scholar
• Mitra AK, Crews KR, Pounds S, et al. Genetic variants in cytosolic 5ʹ-nucleotidase II are associated with its expression and cytarabine sensitivity in HapMap cell lines and in patients with acute myeloid leukemia. J Pharmacol Exp Ther. 2011;339(1):9–23. doi:10.1124/jpet.111.18287321712425
   PubMed Web of Science ®Google Scholar
• Schneider C, Oellerich T, Baldauf H-M, et al. SAMHD1 is a biomarker for cytarabine response and a therapeutic target in acute myeloid leukemia. Nat Med. 2017;23(2):250–255. doi:10.1038/nm.425527991919
   PubMed Web of Science ®Google Scholar
• Garzon R, Savona M, Baz R, et al. A phase 1 clinical trial of single-agent selinexor in acute myeloid leukemia. Blood. 2017;129(24):3165–3174. doi:10.1182/blood-2016-11-75015828336527
   PubMed Web of Science ®Google Scholar
• Martelli MP, Gionfriddo I, Mezzasoma F, et al. Arsenic trioxide and all-trans retinoic acid target NPM1 mutant oncoprotein levels and induce apoptosis in NPM1-mutated AML cells. Blood. 2015;125(22):3455–3465. doi:10.1182/blood-2014-11-61145925795919
   PubMed Web of Science ®Google Scholar
• Karathedath S, Rajamani BM, Aalam SMM, et al. Role of NF-E2 related factor 2 (Nrf2) on chemotherapy resistance in acute myeloid leukemia (AML) and the effect of pharmacological inhibition of Nrf2. PLoS One. 2017;12(5):e0177227. doi:10.1371/journal.pone.017722728505160
   PubMed Web of Science ®Google Scholar
• Ganesan S, Alex AA, Chendamarai E, et al. Rationale and efficacy of proteasome inhibitor combined with arsenic trioxide in the treatment of acute promyelocytic leukemia. Leukemia. 2016;30(11):2169–2178. doi:10.1038/leu.2016.22727560113
   PubMed Web of Science ®Google Scholar
• Skrtić M, Sriskanthadevan S, Jhas B, et al. Inhibition of mitochondrial translation as a therapeutic strategy for human acute myeloid leukemia. Cancer Cell. 2011;20(5):674–688. doi:10.1016/j.ccr.2011.10.01522094260
   PubMed Web of Science ®Google Scholar
• Tardi P, Johnstone S, Harasym N, et al. In vivo maintenance of synergistic cytarabine: daunorubicinratios greatly enhances therapeutic efficacy. Leuk Res. 2009;33(1):129–139. doi:10.1016/j.leukres.2008.06.02818676016
   PubMed Web of Science ®Google Scholar
• Lim W-S, Tardi PG, Dos Santos N, et al. Leukemia-selective uptake and cytotoxicity of CPX-351, a synergistic fixed-ratio cytarabine: daunorubicinformulation, in bone marrow xenografts. Leuk Res. 2010;34(9):1214–1223. doi:10.1016/j.leukres.2010.01.01520138667
   PubMed Web of Science ®Google Scholar
• Mayer LD, Harasym TO, Tardi PG, et al. Ratiometric dosing of anticancer drug combinations: controlling drug ratios after systemic administration regulates therapeutic activity in tumor-bearing mice. Mol Cancer Ther. 2006;5(7):1854–1863. doi:10.1158/1535-7163.MCT-06-011816891472
   PubMed Web of Science ®Google Scholar
• Lancet JE, Uy GL, Cortes JE, et al. CPX-351 (cytarabine and daunorubicin) liposome for injection versus conventional cytarabine plus daunorubicin in older patients with newly diagnosed secondary acute myeloid leukemia. J Clin Oncol. 2018;36(26):2684–2692. doi:10.1200/JCO.2017.77.611230024784
   PubMed Web of Science ®Google Scholar
• Glover AB, Leyland-Jones B. Biochemistry of azacitidine: a review. Cancer Treat Rep. 1987;71(10):959–964.2443243
   PubMedGoogle Scholar
• Silverman LR, McKenzie DR, Peterson BL, et al. Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8421, 8921, and 9221 by the cancer and leukemia group B. J Clin Oncol. 2006;24(24):3895–3903. doi:10.1200/JCO.2005.05.434616921040
   PubMed Web of Science ®Google Scholar
• Savona MR, Gore SD, Kolibaba KS, et al. CC-486 (oral azacitidine) monotherapy in patients with acute myeloid leukemia (AML). Blood. 2015;126(23): 452–452.
   Google Scholar
• Savona MR, Kolibaba K, Conkling P, et al. Extended dosing with CC-486 (oral azacitidine) in patients with myeloid malignancies. Am J Hematol. 2018;93(10):1199–1206. doi:10.1002/ajh.2521630016552
   PubMed Web of Science ®Google Scholar
• Roosendaal J, Wang K, Rosing H, et al. Development and validation of LC-MS/MS methods for the quantification of the novel anticancer agent guadecitabine and its active metabolite β‑decitabine in human plasma, whole blood and urine. J Chromatogr B Analyt Technol Biomed Life Sci. 2019;1109:132–141. doi:10.1016/j.jchromb.2019.01.011
   Web of Science ®Google Scholar
• Kantarjian HM, Roboz GJ, Kropf PL, et al. Guadecitabine (SGI-110) in treatment-naive patients with acute myeloid leukaemia: phase 2 results from a multicentre, randomised, phase 1/2 trial. Lancet Oncol. 2017;18(10):1317–1326. doi:10.1016/S1470-2045(17)30576-428844816
   PubMed Web of Science ®Google Scholar
• Lu C, Ward PS, Kapoor GS, et al. IDH mutation impairs histone demethylation and results in a block to cell differentiation. Nature. 2012;483(7390):474–478. doi:10.1038/nature1086022343901
   PubMed Web of Science ®Google Scholar
• Medeiros BC, Fathi AT, DiNardo CD, Pollyea DA, Chan SM, Swords R. Isocitrate dehydrogenase mutations in myeloid malignancies. Leukemia. 2017;31(2):272–281. doi:10.1038/leu.2016.27527721426
   PubMed Web of Science ®Google Scholar
• Figueroa ME, Abdel-Wahab O, Lu C, et al. Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell. 2010;18(6):553–567. doi:10.1016/j.ccr.2010.11.01521130701
   PubMed Web of Science ®Google Scholar
• Xu W, Yang H, Liu Y, et al. Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of α-ketoglutarate-dependent dioxygenases. Cancer Cell. 2011;19(1):17–30. doi:10.1016/j.ccr.2010.12.01421251613
   PubMed Web of Science ®Google Scholar
• Ward PS, Patel J, Wise DR, et al. The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting α-ketoglutarate to 2-hydroxyglutarate. Cancer Cell. 2010;17(3):225–234. doi:10.1016/j.ccr.2010.01.02020171147
   PubMed Web of Science ®Google Scholar
• Ward PS, Lu C, Cross JR, et al. The potential for isocitrate dehydrogenase mutations to produce 2-hydroxyglutarate depends on allele specificity and subcellular compartmentalization. J Biol Chem. 2013;288(6):3804–3815. doi:10.1074/jbc.M112.43549523264629
   PubMed Web of Science ®Google Scholar
• Stein EM, DiNardo CD, Pollyea DA, et al. Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia. Blood. 2017;130(6):722–731. doi:10.1182/blood-2017-04-77940528588020
   PubMed Web of Science ®Google Scholar
• DiNardo CD, Stein AS, Fathi AT, et al. Mutant isocitrate dehydrogenase (mIDH) inhibitors, enasidenib or ivosidenib, in combination with azacitidine (AZA): preliminary results of a Phase 1b/2 study in patients with newly diagnosed acute myeloid leukemia (AML). Blood. 2017;130(Suppl 1): 639–639.
   Google Scholar
• DiNardo CD, Stein EM, de Botton S, et al. Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML. N Engl J Med. 2018. doi:10.1056/NEJMoa1716984
   Web of Science ®Google Scholar
• Fathi AT, DiNardo CD, Kline I, et al. Differentiation syndrome associated with enasidenib, a selective inhibitor of mutant isocitrate dehydrogenase 2: analysis of a Phase 1/2 study. JAMA Oncol. 2018;4(8):1106–1110. doi:10.1001/jamaoncol.2017.469529346478
   PubMed Web of Science ®Google Scholar
• Kelly LM, Liu Q, Kutok JL, Williams IR, Boulton CL, Gilliland DG. FLT3 internal tandem duplication mutations associated with human acute myeloid leukemias induce myeloproliferative disease in a murine bone marrow transplant model. Blood. 2002;99(1):310–318. doi:10.1182/blood.V99.1.31011756186
   PubMed Web of Science ®Google Scholar
• Yanada M, Matsuo K, Suzuki T, Kiyoi H, Naoe T. Prognostic significance of FLT3 internal tandem duplication and tyrosine kinase domain mutations for acute myeloid leukemia: a meta-analysis. Leukemia. 2005;19(8):1345–1349. doi:10.1038/sj.leu.240383815959528
   PubMed Web of Science ®Google Scholar
• Thiede C, Steudel C, Mohr B, et al. Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis. Blood. 2002;99(12):4326–4335. doi:10.1182/blood.v99.12.432612036858
   PubMed Web of Science ®Google Scholar
• Döhner H, Estey E, Grimwade D, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129(4):424–447. doi:10.1182/blood-2016-08-73319627895058
   PubMed Web of Science ®Google Scholar
• Brunet S, Labopin M, Esteve J, et al. Impact of FLT3 internal tandem duplication on the outcome of related and unrelated hematopoietic transplantation for adult acute myeloid leukemia in first remission: a retrospective analysis. J Clin Oncol. 2012;30(7):735–741. doi:10.1200/JCO.2011.36.986822291086
   PubMed Web of Science ®Google Scholar
• Deol A, Sengsayadeth S, Ahn KW, et al. Does FLT3 mutation impact survival after hematopoietic stem cell transplantation for acute myeloid leukemia? A Center for International Blood and Marrow Transplant Research (CIBMTR) analysis. Cancer. 2016;122(19):3005–3014. doi:10.1002/cncr.3014027315441
   PubMed Web of Science ®Google Scholar
• Weisberg E, Boulton C, Kelly LM, et al. Inhibition of mutant FLT3 receptors in leukemia cells by the small molecule tyrosine kinase inhibitor PKC412. Cancer Cell. 2002;1(5):433–443.12124173
   PubMed Web of Science ®Google Scholar
• Stone RM, DeAngelo DJ, Klimek V, et al. Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412. Blood. 2005;105(1):54–60. doi:10.1182/blood-2004-03-089115345597
   PubMed Web of Science ®Google Scholar
• Stone RM, Manley PW, Larson RA, Capdeville R. Midostaurin: its odyssey from discovery to approval for treating acute myeloid leukemia and advanced systemic mastocytosis. Blood Adv. 2018;2(4):444–453. doi:10.1182/bloodadvances.201701108029487059
   PubMed Web of Science ®Google Scholar
• Stone RM, Mandrekar SJ, Sanford BL, et al. Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 mutation. N Engl J Med. 2017;377(5):454–464. doi:10.1056/NEJMoa161435928644114
   PubMed Web of Science ®Google Scholar
• Fischer T, Stone RM, DeAngelo DJ, et al. Phase IIB trial of oral midostaurin (PKC412), the FMS-like tyrosine kinase 3 receptor (FLT3) and multi-targeted kinase inhibitor, in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome with either wild-type or mutated FLT3. J Clin Oncol. 2010;28(28):4339–4345. doi:10.1200/JCO.2010.28.967820733134
   PubMed Web of Science ®Google Scholar
• Staudt D, Murray HC, McLachlan T, et al. Targeting oncogenic signaling in mutant FLT3 acute myeloid leukemia: the path to least resistance. Int J Mol Sci. 2018;19:10. doi:10.3390/ijms19103198
   Web of Science ®Google Scholar
• Pratz KW, Cherry M, Altman JK, et al. Updated results from a Phase 1 study of gilteritinib in combination with induction and consolidation chemotherapy in subjects with newly diagnosed acute myeloid leukemia (AML). Blood. 2018;132(Suppl1): 564–564. doi:10.1182/blood-2018-99-110975
   Web of Science ®Google Scholar
• Wang ES, Tallman MS, Stone RM, et al. Low relapse rate in younger patients ≤ 60 years old with newly diagnosed FLT3-mutated acute myeloid leukemia (AML) treated with crenolanib and cytarabine/anthracycline chemotherapy. Blood. 2017;130(Suppl 1): 566–566.
   Google Scholar
• Altman JK, Foran JM, Pratz KW, Trone D, Cortes JE, Tallman MS. Phase 1 study of quizartinib in combination with induction and consolidation chemotherapy in patients with newly diagnosed acute myeloid leukemia. Am J Hematol. 2018;93(2):213–221. doi:10.1002/ajh.2497429139135
   PubMed Web of Science ®Google Scholar
• Perl AE, Altman JK, Cortes J, et al. Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1-2 study. Lancet Oncol. 2017;18(8):1061–1075. doi:10.1016/S1470-2045(17)30416-328645776
   PubMed Web of Science ®Google Scholar
• Cortes JE, Kantarjian HM, Kadia TM, et al. Crenolanib besylate, a type I pan-FLT3 inhibitor, to demonstrate clinical activity in multiply relapsed FLT3-ITD and D835 AML. J Clin Oncol. 2016;34(15_suppl):7008. doi:10.1200/JCO.2016.34.15_suppl.7008
   Web of Science ®Google Scholar
• Cortes J, Perl AE, Döhner H, et al. Quizartinib, an FLT3 inhibitor, as monotherapy in patients with relapsed or refractory acute myeloid leukaemia: an open-label, multicentre, single-arm, phase 2 trial. Lancet Oncol. 2018;19(7):889–903. doi:10.1016/S1470-2045(18)30240-729859851
   PubMed Web of Science ®Google Scholar
• Sato T, Yang X, Knapper S, et al. FLT3 ligand impedes the efficacy of FLT3 inhibitors in vitro and in vivo. Blood. 2011;117(12):3286–3293. doi:10.1182/blood-2010-01-26674221263155
   PubMed Web of Science ®Google Scholar
• Al-Jamal HAN, Mat Jusoh SA, Hassan R, Johan MF. Enhancing SHP-1 expression with 5-azacytidine may inhibit STAT3 activation and confer sensitivity in lestaurtinib (CEP-701)-resistant FLT3-ITD positive acute myeloid leukemia. BMC Cancer. 2015;15:869. doi:10.1186/s12885-015-1695-x26547689
   PubMed Web of Science ®Google Scholar
• Godwin CD, Gale RP, Walter RB. Gemtuzumab ozogamicin in acute myeloid leukemia. Leukemia. 2017;31(9):1855–1868. doi:10.1038/leu.2017.18728607471
   PubMed Web of Science ®Google Scholar
• DeStefano CB, Hourigan CS. Personalizing initial therapy in acute myeloid leukemia: incorporating novel agents into clinical practice. Ther Adv Hematol. 2018;9(5):109–121. doi:10.1177/204062071876177829713444
   PubMed Web of Science ®Google Scholar
• van der Velden VHJ, Te Marvelde JG, Hoogeveen PG, et al. Targeting of the CD33-calicheamicin immunoconjugate Mylotarg (CMA-676) in acute myeloid leukemia: in vivo and in vitro saturation and internalization by leukemic and normal myeloid cells. Blood. 2001;97(10):3197–3204. doi:10.1182/blood.V97.10.319711342449
   PubMed Web of Science ®Google Scholar
• Bross PF, Beitz J, Chen G, et al. Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia. Clin Cancer Res. 2001;7(6):1490–1496.11410481
   PubMed Web of Science ®Google Scholar
• Larson RA, Boogaerts M, Estey E, et al. Antibody-targeted chemotherapy of older patients with acute myeloid leukemia in first relapse using Mylotarg (gemtuzumab ozogamicin). Leukemia. 2002;16(9):1627–1636. doi:10.1038/sj.leu.240267712200674
   PubMed Web of Science ®Google Scholar
• Sperr WR, Florian S, Hauswirth AW, Valent P. CD 33 as a target of therapy in acute myeloid leukemia: current status and future perspectives. Leuk Lymphoma. 2005;46(8):1115–1120. doi:10.1080/1042819050012607516085551
   PubMed Web of Science ®Google Scholar
• Jen EY, Ko C-W, Lee JE, et al. FDA approval: gemtuzumab ozogamicin for the treatment of adults with newly diagnosed CD33-positive acute myeloid leukemia. Clin Cancer Res. 2018;24(14):3242–3246. doi:10.1158/1078-0432.CCR-17-317929476018
   PubMed Web of Science ®Google Scholar
• Raj RV, Abedin SM, Atallah E. Incorporating newer agents in the treatment of acute myeloid leukemia. Leuk Res. 2018;74:113–120. doi:10.1016/j.leukres.2018.10.00830401522
   PubMed Web of Science ®Google Scholar
• Gottardi M, Mosna F, de Angeli S, et al. Clinical and experimental efficacy of gemtuzumab ozogamicin in core binding factor acute myeloid leukemia. Hematol Rep. 2017;9(3). doi:10.4081/hr.2017.7028
   Web of Science ®Google Scholar
• Linenberger ML, Hong T, Flowers D, et al. Multidrug-resistance phenotype and clinical responses to gemtuzumab ozogamicin. Blood. 2001;98(4):988–994. doi:10.1182/blood.v98.4.98811493443
   PubMed Web of Science ®Google Scholar
• Thomas D, Majeti R. Biology and relevance of human acute myeloid leukemia stem cells. Blood. 2017;129(12):1577–1585. doi:10.1182/blood-2016-10-69605428159741
   PubMed Web of Science ®Google Scholar
• Del Poeta G, Venditti A, Aronica G, et al. P-glycoprotein expression in de novo acute myeloid leukemia. Leuk Lymphoma. 1997;27(3–4):257–274. doi:10.3109/104281997090596829402325
   PubMed Web of Science ®Google Scholar
• Lutterbach B, Sun D, Schuetz J, Hiebert SW. The MYND motif is required for repression of basal transcription from the multidrug resistance 1 promoter by the t(8;21) fusion protein. Mol Cell Biol. 1998;18(6):3604–3611. doi:10.1128/mcb.18.6.36049584201
   PubMed Web of Science ®Google Scholar
• Pollyea DA, Jordan CT. Therapeutic targeting of acute myeloid leukemia stem cells. Blood. 2017;129(12):1627–1635. doi:10.1182/blood-2016-10-69603928159738
   PubMed Web of Science ®Google Scholar
• Assi R, Kantarjian H, Ravandi F, Daver N. Immune therapies in acute myeloid leukemia: a focus on monoclonal antibodies and immune checkpoint inhibitors. Curr Opin Hematol. 2018;25(2):136–145. doi:10.1097/MOH.000000000000040129206680
   PubMed Web of Science ®Google Scholar
• Yalcintepe L, Frankel AE, Hogge DE. Expression of interleukin-3 receptor subunits on defined subpopulations of acute myeloid leukemia blasts predicts the cytotoxicity of diphtheria toxin interleukin-3 fusion protein against malignant progenitors that engraft in immunodeficient mice. Blood. 2006;108(10):3530–3537. doi:10.1182/blood-2006-04-01381316882709
   PubMed Web of Science ®Google Scholar
• Sweet KL, Pemmaraju N, Lane AA, et al. Lead-in stage results of a pivotal trial of SL-401, an interleukin-3 receptor (IL-3R) targeting biologic, in patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN) or acute myeloid leukemia (AML). Blood. 2015;126(23): 3795–3795.
   Web of Science ®Google Scholar
• Campagne O, Delmas A, Fouliard S, et al. Integrated pharmacokinetic/pharmacodynamic model of a bispecific CD3xCD123 DART molecule in nonhuman primates: evaluation of activity and impact of immunogenicity. Clin Cancer Res. 2018;24(11):2631–2641. doi:10.1158/1078-0432.CCR-17-226529463552
   PubMed Web of Science ®Google Scholar
• Uy GL, Godwin J, Rettig MP, et al. Preliminary results of a Phase 1 study of flotetuzumab, a CD123 x CD3 Bispecific Dart® protein, in patients with relapsed/refractory acute myeloid leukemia and myelodysplastic syndrome. Blood. 2017;130(Suppl 1): 637–637.
   Google Scholar
• Ok CY, Patel KP, Garcia-Manero G, et al. TP53 mutation characteristics in therapy-related myelodysplastic syndromes and acute myeloid leukemia is similar to de novo diseases. J Hematol Oncol. 2015;8:45. doi:10.1186/s13045-015-0139-z25952993
   PubMed Web of Science ®Google Scholar
• Lambert JMR, Gorzov P, Veprintsev DB, et al. PRIMA-1 reactivates mutant p53 by covalent binding to the core domain. Cancer Cell. 2009;15(5):376–388. doi:10.1016/j.ccr.2009.03.00319411067
   PubMed Web of Science ®Google Scholar
• Sallman DA, DeZern A, Sweet K, et al. Abstract CT068: Phase Ib/II combination study of APR-246 and azacitidine (AZA) in patients with TP53 mutant myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). Cancer Res. 2018;78(13 Supplement):CT068–CT068. doi:10.1158/1538-7445.AM2018-CT068
   Web of Science ®Google Scholar
• Anstee NS, Bilardi RA, Ng AP, et al. Impact of elevated anti-apoptotic MCL-1 and BCL-2 on the development and treatment of MLL-AF9 AML in mice. Cell Death Differ. 2018;1. doi:10.1038/s41418-018-0209-1
   Web of Science ®Google Scholar
• Lagadinou ED, Sach A, Callahan K, et al. BCL-2 inhibition targets oxidative phosphorylation and selectively eradicates quiescent human leukemia stem cells. Cell Stem Cell. 2013;12(3):329–341. doi:10.1016/j.stem.2012.12.01323333149
   PubMed Web of Science ®Google Scholar
• Thomas XG, Dmoszynska A, Wierzbowska A, et al. Results from a randomized phase III trial of decitabine versus supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed AML. J Clin Oncol. 2011;29(15_suppl): 6504–6504. doi:10.1200/jco.2011.29.15_suppl.6504
   Web of Science ®Google Scholar
• DiNardo CD, Pratz K, Pullarkat V, et al. Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia. Blood. 2019;133(1):7–17. doi:10.1182/blood-2018-08-86875230361262
   PubMed Web of Science ®Google Scholar
• Pollyea DA, Stevens BM, Jones CL, et al. Venetoclax with azacitidine disrupts energy metabolism and targets leukemia stem cells in patients with acute myeloid leukemia. Nat Med. 2018;24(12):1859–1866. doi:10.1038/s41591-018-0233-130420752
   PubMed Web of Science ®Google Scholar
• Ganapule A, Nemani S, Korula A, et al. Allogeneic stem cell transplant for acute myeloid leukemia: evolution of an effective strategy in India. J Glob Oncol. 2017;3(6):773–781. doi:10.1200/JGO.2016.00665029244983
   PubMed Web of Science ®Google Scholar
• Lipof JJ, Loh KP, O’Dwyer K, Liesveld JL. Allogeneic hematopoietic cell transplantation for older adults with acute myeloid leukemia. Cancers. 2018;10(6):179. doi:10.3390/cancers10060179
   PubMed Web of Science ®Google Scholar
• Brodská B, Fuchs O, Otevřelová P, Salek C, Kuželová K. PD-L1 Is frequently expressed in acute myeloid leukemia patients with leukocytosis. Blood. 2016;128(22): 5229–5229.
   Web of Science ®Google Scholar
• Haroun F, Solola SA, Nassereddine S, Tabbara I. PD-1 signaling and inhibition in AML and MDS. Ann Hematol. 2017;96(9):1441–1448. doi:10.1007/s00277-017-3051-528643044
   PubMed Web of Science ®Google Scholar
• Daver N, Garcia-Manero G, Basu S, et al. Nivolumab (Nivo) with azacytidine (AZA) in patients (pts) with relapsed acute myeloid leukemia (AML) or frontline elderly AML. Blood. 2017;130(Suppl 1): 1345–1345.
   Google Scholar
• Ravandi F, Daver N, Garcia-Manero G, et al. Phase 2 study of combination of cytarabine, idarubicin, and nivolumab for initial therapy of patients with newly diagnosed acute myeloid leukemia. Blood. 2017;130(Suppl 1): 815–815.
   Google Scholar
• Parmar S, Tallman MS. Acute promyelocytic leukaemia: a review. Expert Opin Pharmacother. 2003;4(8):1379–1392. doi:10.1517/14656566.4.8.137912877645
   PubMed Web of Science ®Google Scholar
• Lo-Coco F, Avvisati G, Vignetti M, et al. Retinoic acid and arsenic trioxide for acute promyelocytic leukemia. N Engl J Med. 2013;369(2):111–121. doi:10.1056/NEJMoa130087423841729
   PubMed Web of Science ®Google Scholar
• Welch JS, Ley TJ, Link DC, et al. The origin and evolution of mutations in acute myeloid leukemia. Cell. 2012;150(2):264–278. doi:10.1016/j.cell.2012.06.02322817890
   PubMed Web of Science ®Google Scholar
• Metzeler KH, Herold T, Rothenberg-Thurley M, et al. Spectrum and prognostic relevance of driver gene mutations in acute myeloid leukemia. Blood. 2016;128(5):686–698. doi:10.1182/blood-2016-01-69387927288520
   PubMed Web of Science ®Google Scholar
• Eriksson A, Österroos A, Hassan S, et al. Drug screen in patient cells suggests quinacrine to be repositioned for treatment of acute myeloid leukemia. Blood Cancer J. 2015;5(4):e307. doi:10.1038/bcj.2015.3125885427
   PubMed Web of Science ®Google Scholar
• Lee S-I, Celik S, Logsdon BA, et al. A machine learning approach to integrate big data for precision medicine in acute myeloid leukemia. Nat Commun. 2018;9(1):42. doi:10.1038/s41467-017-02465-529298978
   PubMed Web of Science ®Google Scholar
• Azzam D, Volmar C-H, Hassan -A-A, et al. A patient-specific ex vivo screening platform for personalized acute myeloid leukemia (AML) therapy. Blood. 2015;126(23): 1352–1352.
   Web of Science ®Google Scholar